Corneal Versus Conjunctival Delivery Using a Delivery Device

This study has been withdrawn prior to recruitment.

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00143429

Purpose

Compare the antihypertensive efficacy of three methods for installing Xalatan

Condition	Intervention	Phase
Glaucoma, Open-Angle Ocular Hypertension	Drug: Xalatan	Phase II

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma High Blood Pressure

Drug Information available for: Latanoprost

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Active Control, Crossover Assignment, Safety/Efficacy Study
Official Title:	Effect Of Corneal Versus Conjunctival Delivery On The Corneal Safety, Tolerability, and Antihypertensive Efficacy Of The Xalatan Ophthalmic Delivery Device

Further study details as provided by Pfizer:

Primary Outcome Measures:

Secondary Outcome Measures:

Change in ocular safety assessments. Ocular and systemic adverse events throughout the study period

Estimated Enrollment:

Eligibility

Criteria

Inclusion Criteria:

Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes

Exclusion Criteria:

History of closed/barely open anterior chamber angle or a history of angle closure

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00143429

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Study ID Numbers:	A6111127
Study First Received:	September 1, 2005
Last Updated:	March 1, 2007
ClinicalTrials.gov Identifier:	NCT00143429
Health Authority:	United States: Food and Drug Administration

Keywords provided by Pfizer:

Primary Open Angle Glaucoma

Study placed in the following topic categories:

Glaucoma
Eye Diseases
Glaucoma, Open-Angle
Vascular Diseases

Latanoprost
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:

Therapeutic Uses
Cardiovascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009